scholarly journals Dupilumab treatment of a case of asthma, chronic rhinosinusitis, and atopic dermatitis after initial benralizumab administration

2020 ◽  
Vol 3 (4) ◽  
pp. 91-93
Author(s):  
Haruna Matsuda‐Hirose ◽  
Naoko Takeo ◽  
Masaru Ando ◽  
Yumi Kizu ◽  
Yutaka Hatano
Keyword(s):  
Atopic Dermatitis ◽  
Chronic Rhinosinusitis

Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis

2021 ◽  
Author(s):  
Maddalena Napolitano ◽  
Marianna Maffei ◽  
Cataldo Patruno ◽  
Carlo Antonio Leone ◽  
Adriana Guida ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Chronic Rhinosinusitis ◽  
Nasal Polyposis

Role of Superantigens in Allergic Inflammation: Their Relationship to Allergic Rhinitis, Chronic Rhinosinusitis, Asthma, and Atopic Dermatitis

2018 ◽  
Vol 32 (6) ◽  
pp. 502-517 ◽  
Author(s):  
Nuray Bayar Muluk ◽  
Fazilet Altın ◽  
Cemal Cingi
Keyword(s):  
T Cells ◽  
Allergic Rhinitis ◽  
Atopic Dermatitis ◽  
Inflammatory Response ◽  
Chronic Rhinosinusitis ◽  
Inflammatory Responses ◽  
Immunoglobulin E ◽  
Severe Disease ◽  
Allergic Inflammation ◽  
Allergic Dermatitis

Objectives Our intention was to review all material published to date regarding superantigens (SAgs) and allergy from an otorhinolaryngological viewpoint to understand this association more clearly. Methods We identified all materials published mentioning both SAg and allergic rhinitis (AR), chronic sinusitis, asthma, and atopic dermatitis (AD) that are indexed on PubMed, Google, or the ProQuest Central databases. Results Staphylococcus aureus is a significant bacterial pathogen in humans and has the ability to produce enterotoxins with superantigenic features. The inflammatory response in allergy seen in both B cell and T cell may be attributed to SAgs. Sufferers of both allergic asthma with rhinitis and AR alone produce serological evidence of immunoglobulin E formation to SAgs produced by S. aureus. Perennial AR sufferers carry S. aureus more frequently and the presence of the organism within the nasal cavity may exacerbate perennial AR. SAg produced by S. aureus potentially worsens the asthmatic inflammatory response within the airway and may lead to the airways becoming hyperresponsive, as well as possibly activating T cells if asthmatic control is poor. Staphylococcal SAgs potentially increase the risk of developing chronic rhinosinusitis with nasal polyposis, additionally being a marker for more severe disease. If SAgs bring about chronic inflammatory responses in the nose and sinuses, then T cells excreting interferon-gamma may be a crucial mediator. In allergic dermatitis, S. aureus could be a key player in exacerbation of the condition. Even in younger pediatric patients with allergic dermatitis, allergic hypersensitivity to SAgs is frequent and may be a factor explaining how severe the condition becomes. Conclusion Just as SAgs are known to feature in many allergic conditions, they play their part in AR, chronic rhinosinusitis, asthma, and AD. Further research is required before the relationship between SAgs and allergy can be adequately explained.

scholarly journals Gene Transcription Changes in Asthmatic Chronic Rhinosinusitis with Nasal Polyps and Comparison to Those in Atopic Dermatitis

PLoS ONE ◽  
2010 ◽  
Vol 5 (7) ◽  
pp. e11450 ◽  
Author(s):  
Douglas A. Plager ◽  
Jane C. Kahl ◽  
Yan W. Asmann ◽  
Allan E. Nilson ◽  
John F. Pallanch ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Chronic Rhinosinusitis ◽  
Gene Transcription ◽  
Nasal Polyps

scholarly journals Efficacy of Dupilumab in Concomitant Atopic Dermatitis and Chronic Rhinosinusitis With Nasal Polyps: A Preliminary Study

2021 ◽  
Vol 13 (2) ◽  
pp. 347
Author(s):  
Eustachio Nettis ◽  
Vincenzo Patella ◽  
Raffaele Brancaccio ◽  
Caterina Detoraki ◽  
Elisabetta Di Leo ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Chronic Rhinosinusitis ◽  
Nasal Polyps ◽  
Preliminary Study

T2 asthma and T2-associated diseases: a consolidated approach to biological therapy

2020 ◽  
Vol 17 (3) ◽  
pp. 34-49
Author(s):  
Natalya M. Nenasheva
Keyword(s):  
Atopic Dermatitis ◽  
Chronic Rhinosinusitis ◽  
Nasal Polyps ◽  
Biological Therapy ◽  
Human Monoclonal Antibody ◽  
Experimental Studies ◽  
Smooth Muscles ◽  
Associated Diseases ◽  
Steroid Dependent

This article is dedicated to the main characteristics of severe bronchial asthma (SBA) and its heterogeneity. In particular, it describes T2 asthma and the role of the main cytokines involved in T2 inflammation. It focuses on the role of IL-4 and IL-13 in the pathogenesis of asthma and other T2-associated diseases, as key cytokines in the initiation and maintenance of T2 inflammation. The article presents the results of experimental studies proving that the activation of IL-4/IL-13 can cause significant hyperresponsiveness of the human airway smooth muscles and the combined blockade of the activity of these cytokines using a human monoclonal antibody against the common IL-4/13 receptor-subunit-dupilumab-determines the clinical efficacy not only in relation to exacerbations and control of asthma symptoms, but also an improvement of the lung function and a reduction in bronchial hyperresponsiveness. When type 2 helper cells (Th2) interact with antigen-presenting cells, IL-4 and IL-13 are simultaneously released, therefore, blocking IL-4Ris more effective than blocking each of the ligands separately, which explains the high efficacy of dupilumab not only in T2 asthma, but also other T2-associated diseases: atopic dermatitis and chronic rhinosinusitis with nasal polyps. In addition to asthma and atopic dermatitis, a new indication for dupilumab, chronic rhinosinusitis with nasal polyps, has recently been approved. According to the recommendations of the European Academy of Allergy and Clinical Immunology (EAACI) for the biological therapy of SBA 2020, dupilumab is recommended as an add-on maintenance therapy in adults and children aged 1217 years old with uncontrolled severe T2 asthma, including asthma with the allergic and eosinophilic phenotype, as well as mixed (when there are signs of both phenotypes) and steroid-dependent asthma. At the same time, dupilumab is well tolerated.

Sign in / Sign up

Export Citation Format

Share Document